E PRIN Actions

Is this medication very expensive?
sponsored

Actions of E PRIN in details

sponsored

Antithrombotic.

Pharmacology: Pharmacodynamics: E PRIN is a nonsteroidal anti-inflammatory agent. The antithrombotic activity of E PRIN is due to its inhibitory effect on platelets which is mediated via irreversible acetylation of platelet cyclooxygenase with subsequent blockade of platelet thromboxane synthesis. The inhibitory effect of E PRIN on platelet thromboxane production persists for the lifespan of the platelet, around 7-10 days. As a result, acetylation of platelet cyclooxygenase and consequent inhibition of thromboxane formation is cumulative on repeated dosing.

Low doses of E PRIN inhibit platelet aggregation and may be more effective than higher doses. Larger doses inhibit cyclooxygenase in arterial walls, interfering with prostacyclin production, a potent vasodilator and inhibitor of platelet aggregation.

Pharmacokinetics: E PRIN is rapidly absorbed from the gastrointestinal tract. After oral administration, absorption of nonionized E PRIN occurs in the stomach. E PRIN, in an acid-resistant coating, is not released in the stomach but in the alkaline environment of the intestine. Therefore, absorption of E PRIN is delayed by 3-6 hrs and time to achieve mean peak E PRIN concentration is 4-6 hrs after administration of the enteric coated tablet.

E PRIN is rapidly and widely distributed into most body tissues and fluids. The volume of distribution of E PRIN is 0.15-0.2 L/kg. It is poorly bound to plasma proteins; the unhydrolyzed drug is 33% bound at a serum salicylate concentration of 120 mcg/mL.

The elimination t½ of E PRIN is about 15-20 min. Unlike salicylate, unhydrolyzed E PRIN does not undergo capacity-limited metabolism and does not accumulate in plasma after multiple doses. E PRIN is partially hydrolyzed to salicylate during absorption by esterases in the gastrointestinal mucosa after oral administration. After absorption, unhydrolyzed E PRIN is rapidly and almost completely hydrolyzed by esterases principally in the liver but also in plasma, erythrocytes, and synovial fluid; hydrolysis occurs more slowly in synovial fluid since the amounts of esterases in synovial fluid are lower. E PRIN may be hydrolyzed more slowly in women since women apparently have lower amounts of plasma E PRIN esterases. About 1% of an oral E PRIN dose is excreted unhydrolyzed in urine. The remainder is excreted in urine as salicylate and its metabolites.

How should I take E PRIN?

This section provides information on the proper use of a number of products that contain salicylate. It may not be specific to E PRIN. Please read with care.

Take this medicine after meals or with food (except for enteric-coated capsules or tablets and E PRIN suppositories) to lessen stomach irritation.

Take tablet or capsule forms of this medicine with a full glass (8 ounces) of water. Also, do not lie down for about 15 to 30 minutes after swallowing the medicine. This helps to prevent irritation that may lead to trouble in swallowing.

For patients taking E PRIN (including buffered E PRIN and/or products containing caffeine):

To use E PRIN suppositories:

To take choline and magnesium salicylates (e.g., Trilisate) oral solution:

To take enteric-coated sodium salicylate tablets:

Unless otherwise directed by your medical doctor or dentist:

When used for arthritis (rheumatism), this medicine must be taken regularly as ordered by your doctor in order for it to help you. Up to 2 to 3 weeks or longer may pass before you feel the full effects of this medicine.

Dosing

The dose medicines in this class will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of these medicines. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Keep out of the reach of children.

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Do not keep outdated medicine or medicine no longer needed.

E PRIN administration

sponsored

Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger or smaller amounts, or use it for longer than recommended.

Take this medication with a full glass of water.

Taking E PRIN with food or milk can lessen stomach upset. Enteric-coated E PRIN is specially formulated to be gentle on your stomach, but you may take it with food or milk if desired.

Do not crush, chew, break, or open an enteric-coated or extended-release pill. Swallow the pill whole. The enteric-coated pill has a special coating to protect your stomach. Breaking the pill could damage this coating. The extended-release tablet is specially made to release medicine slowly in the body. Breaking this pill would cause too much of the drug to be released at one time.

The chewable tablet form of E PRIN must be chewed before swallowing.

Keep the orally disintegrating tablet in its package until you are ready to take the medicine. Open the package and peel the back cover from the tablet. Using dry hands, place the tablet into your mouth. It will begin to dissolve right away, without water. Do not swallow the tablet whole. Allow it to dissolve in your mouth without chewing.

If you need to have any type of surgery, tell the surgeon ahead of time that you are taking E PRIN. You may need to stop using the medicine for a short time.

Do not take this medication if you smell a strong vinegar odor in the E PRIN bottle. The medicine may no longer be effective.

Store E PRIN at room temperature away from moisture and heat.

E PRIN pharmacology

sponsored

Mechanism of Action

E PRIN [acetylsalicylic acid (ASA)] inhibits prostaglandin synthesis resulting in inhibition of platelet aggregation for their lifespan of about 7-10 days. The acetyl group of E PRIN binds with a serine residue of cyclooxygenase-1 (COX-1), resulting in irreversible inactivation of the enzyme. Inhibition of COX-1 prevents conversion of arachidonic acid to thromboxane A2 (TXA2), which is a potent agonist of platelet aggregation.

Pharmacodynamics

The dose-response relationship for E PRIN and immediate release (IR) E PRIN towards COX-1 inhibition was characterized by examining the inhibition of serum TXB2 and urine 11-dehydro-TXB2 at 24 h following a single dose. Doses over the range of 20 mg to 325 mg for E PRIN and 5 mg to 81 mg for IR E PRIN respectively were studied. Half-maximal inhibition of serum TXB2 and urine 11-dehydro-TXB2 occurred with doses of E PRIN (ID50) about 2-fold the dose of immediate release (IR) E PRIN. Based on this relationship, the pharmacodynamic effect of E PRIN 162.5 mg is similar to that attained with IR E PRIN 81 mg. The mean inhibition of serum TXB2 following E PRIN (82%) is lower when compared to IR E PRIN 81 mg (93%) following the first dose. However, upon repeat administration, near maximal inhibition of serum TXB2 is achieved, similar to what is achieved following repeated daily doses of IR E PRIN.

Pharmacokinetics

Following oral administration, E PRIN exhibits extended release of E PRIN from the encapsulated microparticles, thereby prolonging the absorption of E PRIN across the GI tract compared to IR E PRIN (Figure 1). Once absorbed, E PRIN is metabolized, distributed, and excreted in a manner similar to that of E PRIN absorbed from IR dosage forms.

Absorption: Following administration of E PRIN, the time to reach peak plasma concentration of E PRIN is slightly longer compared to following IR E PRIN dosage form. Median Tmax for E PRIN is about 2 h when compared to 1 h following IR E PRIN. The mean Cmax for E PRIN is approximately 35% of that following IR E PRIN 81 mg. The area under the plasma concentration-time curve for E PRIN following administration of E PRIN is approximately 70% of that following IR E PRIN. The rate of E PRIN absorption is dependent on food, alcohol, and gastric pH.

Distribution: The volume of distribution of usual doses of E PRIN in normal subjects averages approximately 170 mL/kg of body weight.

Metabolism: E PRIN is rapidly hydrolyzed in the plasma to salicylic acid such that plasma levels of E PRIN following E PRIN administration are essentially undetectable 4-8 hours after dosing. In contrast to immediate release E PRIN, measurable levels of salicylic acid at 24 hours following a single dose of E PRIN were observed. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites.

Elimination: The mean plasma half-life of E PRIN may range from 20 to 60 min. Following therapeutic doses, approximately 10% is found excreted in the urine as salicylic acid, 75% as salicylic acid, and 10% phenolic and 5% acyl glucuronides of salicylic acid.



References

  1. DailyMed. "ASPIRIN; DIPYRIDAMOLE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. NCIt. "Aspirin: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).
  3. EPA DSStox. "Aspirin: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/ds... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for E PRIN are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking E PRIN. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported administration

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 19 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved